March 2016, Vol. 5, No. 2

← Back to Issue

Regular Aspirin Use Reduces the Risk for Prostate Cancer Death

Genitourinary Cancers Symposium

The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer according to the results from a large observational study reported at the Genitourinary Cancers Symposium. For the purposes of this study, lethal prostate cancer was defined as metastatic disease or prostate cancer–specific death.

Aspirin is cheap and widely available, and this evidence suggests a reason to take aspirin in addition to cardiovascular protection. But this does not mean that men with a diagnosis of prostate cancer should add aspirin to their list of medications. First, they should discuss the risks (mainly gastrointestinal bleeding) and benefits of taking aspirin with their oncologist.

“It is premature to recommend aspirin to prevent lethal prostate cancer, but men with prostate cancer who already may benefit from aspirin’s cardiovascular effects could have one more reason to consider regular aspirin use,” said lead investigator Christopher B. Allard, MD, Harvard Program in Urology, Massachusetts General Hospital and Brigham and Women’s Hospital, Boston. “Physicians can discuss these findings with patients,” he added.

The Physicians’ Health Study enrolled 22,071 male physicians. After 27 years of follow-up, 3183 men were diagnosed with prostate cancer, and 402 of them had lethal prostate cancer.

Regular aspirin use (≥3 tablets weekly) reduced the risk for lethal prostate cancer by 24% in the overall trial compared with nonusers, according to a multivariate analysis adjusted for age, race, body mass index, and smoking status. Among men with a diagnosis of prostate cancer, regular aspirin use after diagnosis reduced the risk for prostate cancer–specific death by 39% compared with nonusers.

Allard emphasized that regular aspirin had no effect on the risks for prostate cancer, high-grade prostate cancer, or locally advanced disease.

At a premeeting press cast, he said that he and his colleagues plan to study mechanisms related to aspirin’s effect on lethal prostate cancer and to determine which subsets of men might benefit. Also, the study did not control for the dose of aspirin, so an optimal dose remains to be determined.

“This is a provocative paper, but it is an observational study, and we need formal clinical trials to determine the right dose and the right patients who will benefit. Remember, aspirin causes bleeding,” said press cast moderator Sumanta K. Pal, MD, Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, and an ASCO spokesperson, but who was not involved in this study.

Randomized controlled trials are needed to study the protective effects of aspirin in men with prostate cancer.

ASH 2015, ASH Highlights - March 10, 2016

First-in-Human CAR T-Cell Trial Shows Activity in Multiple Myeloma

CAR T-cell therapy has been striking in various hematologic malignancies, and, for the first time, the approach is being evaluated in multiple myeloma.At the meeting, James Kochenderfer, MD, of the Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, presented preliminary results from a phase [ Read More ]

Genitourinary Cancers Symposium - March 10, 2016

No Benefit from Nephrectomy in High-Risk RCC with Thrombus

High-risk patients with metastatic renal cell carcinoma (RCC) and venous tumor thrombus derived no benefit from cytoreductive nephrectomy and should be evaluated for clinical trials of systemic therapy, a retrospective multicenter review suggested.Patients with thrombus above the diaphragm had a median overall survival of 6.8 months after surgery, about a [ Read More ]